November 2016, Vol 7, No 10

Boston, MA—Are we winning the war on cancer? According to Joshua J. Ofman, MD, MSHS, Senior Vice President, Global Value, Access and Policy, Amgen, the answer is yes. Dr Ofman discussed the economics of cancer, including challenges facing insurance providers and ways to impact the rising cost of cancer care, at the War on Cancer forum hosted by The Economist.
Read Article

San Francisco, CA—For patients with hematologic malignancies, end-of-life care varies but often involves high-intensity interventions as death approaches. According to a recent analysis by Cara L. McDermott, PharmD, PhD, MSc, Senior Fellow, Fred Hutchinson Cancer Research Center, Seattle, WA, and colleagues, these interventions can come with a hefty price tag, too.
Read Article

San Francisco, CA—In addition to improving quality of care and patient satisfaction, palliative care can also save hospitals millions of dollars, according to a study presented by lead investigator Sarina Isenberg, PhD candidate, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. The study’s final analysis showed that expanded patient access to palliative care demonstrated substantial savings to the Johns Hopkins Hospital and Health System and could lead to approximately $20 million in savings in 5 years, said Ms Isenberg at the 2016 Palliative Care in Oncology Symposium.
Read Article

Boston, MA—The issues surrounding the cost of cancer care are large and looming in today’s healthcare landscape, but these problems are nothing compared to what is coming, according to Amitabh Chandra, PhD, Director of Health Policy Research, Harvard Kennedy School of Government, Cambridge, MA, who spoke at the War on Cancer forum organized by The Economist.
Read Article


Copenhagen, Denmark—Two more PD-1 targeted drugs staked a claim to a role in treating advanced urothelial cancer, according to data from 2 studies that were reported at the 2016 European Society for Medical Oncology Congress.
Read Article

Copenhagen, Denmark—Maintenance therapy with niraparib, an oral PARP inhibitor, significantly prolonged progression-free survival (PFS) in patients with recurrent, platinum-sensitive ovarian cancer regardless of their BRCA mutation status and homologous recombination deficiency (HRD) status.
Read Article

Copenhagen, Denmark—The addition of the selective cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib to letrozole (Femara) significantly improved progression-free survival (PFS) in patients with hormone receptor (HR)-positive advanced breast cancer. Compared with letrozole alone, the combination of ribociclib plus letrozole improved PFS by 44%.
Read Article

Boston, MA—Drug pricing in the pharmaceutical industry came under scrutiny at the recent War on Cancer forum organized by The Economist. An expert panel discussed the disassociation between the actual benefits of cancer drugs and their prices.
Read Article


Page 3 of 3